Skip to main content
诺思兰德 logo

诺思兰德 — Investor Relations & Filings

Ticker · 920047 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 539 across all filing types
Latest filing 2023-05-23 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920047

About 诺思兰德

https://www.northland-bio.com/

Northland Biotech focuses on the research, development, and commercialization of gene therapies and recombinant protein pharmaceuticals. The company’s primary therapeutic areas include cardiovascular diseases, peripheral arterial diseases, and ophthalmology. Its core R&D pipeline features NL003, a hepatocyte growth factor gene therapy targeting critical limb ischemia, and NL005, a recombinant human thymosin beta 4 for treating myocardial ischemia. Beyond its innovative pipeline, the company maintains advanced manufacturing facilities for biologics and ophthalmic preparations, producing a range of specialized eye drops. By leveraging its proprietary technology platforms, Northland Biotech aims to provide effective treatments for chronic and degenerative conditions through advanced molecular medicine.

Recent filings

Filing Released Lang Actions
董事长、监事会主席、高级管理人员换届公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the election and appointment of the company's chairman, supervisory board chairman, and senior management personnel. It details the changes in board and management positions, their qualifications, and the legal compliance of the appointments. There is no financial data, earnings information, or report publication mentioned. The content focuses on management changes and governance matters. Therefore, the document fits the category of Board/Management Information (MANG). The document length is 3584 characters, which is consistent with an announcement rather than a full report.
2023-05-23 Chinese
独立董事关于第六届董事会第一次会议相关事项的独立意见公告
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on the appointment of several senior management personnel at Beijing Northland Biotech Co., Ltd. It discusses the legality and qualifications of the appointments, referencing company law and stock exchange rules. There is no financial data, no report publication, no voting results, and no mention of a general meeting or shareholder vote. The content is focused on management appointments and related compliance. Therefore, the document fits best under Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2023-05-23 Chinese
北京海润天睿律师事务所关于北京诺思兰德生物技术股份有限公司2022年年度股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a legal opinion letter from a law firm regarding the 2022 Annual General Meeting (AGM) of Beijing Nuosiland Biotechnology Co., Ltd. It details the convening, attendance, agenda, and voting results of the AGM. The document focuses on the legality and validity of the AGM procedures and resolutions passed. It does not contain the full annual report or financial statements but rather confirms the outcomes of the shareholder votes and the meeting process. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA), which includes official results from shareholder votes at any general meeting. The document length is 7616 characters, which is substantive and not a mere announcement of a report publication. Therefore, the correct classification is DVA.
2023-05-17 Chinese
2022年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the 2022 Annual General Meeting (AGM) of Beijing Northland Biotech Co., Ltd. It includes information about the meeting date, attendance, agenda items, voting results, and legal opinions confirming the validity of the meeting and resolutions. The content focuses on shareholder voting outcomes on various proposals such as board member elections, financial reports, audit appointments, and other corporate matters. It does not contain the full annual report or financial statements but rather the official results and decisions made at the AGM. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length and detail confirm it is not a brief announcement or a simple notice but a comprehensive voting results report from the AGM.
2023-05-17 Chinese
投资者关系活动记录表
Call Transcript Classification · 95% confidence The document is titled as an "投资者关系活动记录表" which translates to "Investor Relations Activity Record". It details an investor relations event held on May 15, 2023, specifically a 2022 annual report earnings explanation meeting (业绩说明会). The content includes Q&A between investors and company management about the 2022 annual report and company operations. The document is relatively short (3903 characters) and focuses on the discussion and explanation of the annual report rather than presenting the full annual report itself. It also references that the 2022 annual report materials and videos are available via a link, indicating this document is a record of the earnings call or investor meeting rather than the report itself. According to the filing definitions, an "业绩说明会" (earnings explanation meeting) corresponds to a Call Transcript (CT). Therefore, this document should be classified as a Call Transcript (CT).
2023-05-15 Chinese
2022年度报告业绩说明会预告公告
AGM Information Classification · 95% confidence The document is a short announcement (1071 characters) about a scheduled performance explanation meeting related to the 2022 Annual Report of Beijing Northland Biotechnology Co., Ltd. It references the 2022 Annual Report and its summary, which were previously disclosed, and invites investors to participate in an online meeting to discuss the report. The document does not contain the actual annual report or detailed financial data but rather announces the upcoming event to explain the annual report results. According to the 'Menu vs Meal' rule, this is an announcement about a report-related event, not the report itself. Therefore, the appropriate classification is AGM Information (AGM-R), as it relates to materials shared during an annual meeting or similar event focused on the annual report.
2023-05-10 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.